A Phase 2 study of XC001 as adjunctive therapy in patients with coronary artery bypass grafting (CABG)
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Encoberminogene rezmadenovec (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Sponsors XyloCor Therapeutics
- 07 Jan 2025 According to XyloCor Therapeutics media release, company aims to initiate a second Phase 2 trial of XC001 in 2025 as an adjunctive therapy to augment the effectiveness of CABG
- 10 Jul 2024 According to XyloCor Therapeutics media release, the company have entered into a licensing agreement under which XyloCor has rights to the Extroducer Infusion Catheter System , a first-in-class endovascular device designed to deliver advanced therapies directly into the heart; XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of XC001
- 29 Jul 2021 New trial record